Nottingham pharmaceutical firm, Sygnature Discovery, has added two new senior scientists to its management team, strengthening its drug metabolism and pharmacokinetics (DMPK) capabilities.
Clive Dilworth has been recruited as Director of DMPK, replacing Tim Schulz-Utermoehl, who had been heading up the team on a part-time basis alongside his work with several biotech start-ups.
Mr Dilworth joins from a management role at the Alderley Park life science campus, where he provided strategic and scientific guidance for start-ups and CROs at the site.
Prior, he spent 20 years working in DMPK roles at various CROs, most recently Cyprotex and Evotec.
Robert Kime joined Sygnature as Associate Director of DMPK in November and reports to Dilworth. He was recruited from the mid-sized pharma company Grünenthal, where he was Associate Scientific Director.
Before that, he had roles at CROs including Quintiles. Robert brings important client-side experience to the team
In addition, Sally Lee has joined as a Principal Scientist bringing over 20 years of DMPK experience in both assay and Project Management roles.
In her previous position at AMR (AntiMicrobial Resistance) Centre, she coordinated DMPK requests for novel antimicrobials targeting the threat of antibiotic resistance.
Sygnature’s DMPK team now numbers 37, with a group of 24 in the Nottingham labs and a further 13 in Alderley Park. Further expansion is planned this year.